Turning up the heat on sarcoma

Principal Investigators: 
Award Amount: 
£7,385

Magnetic nanoparticles will produce heat if exposed to an alternating magnetic field. If magnetic nanoparticles can get inside a tumour, an alternating magnetic field can be applied so that the particles heat up and the tumour cells are killed. This project investigated two different ways to deliver nanoparticles into the tumour using mesenchymal stem cells. One worked, one didn’t, and the group has now secured future funding to keep investigating the method that proved successful.

An investigation into the impact of pharmacogenetic variation on clinical response and toxicity in patients treated with gemcitabine, docetaxel and doxorubicin on the GeDDiS trial.

Principal Investigators: 
Institution: 
Award Amount: 
£22,318

Sarcomas are rare tumours that account for approximately 1% of all cancers in the UK. They represent a challenge to treating clinicians as diagnosis is often delayed and the tumours are commonly in an advanced stage or have spread to other parts of the body. Current treatment approaches for these advanced tumours have shown only modest response rates of 12-24% and are associated with significant toxicity in patients.

Developing and characterizing novel bioactive materials to selectively induce osteosarcoma cell death and simultaneously enhance bone regeneration.

Principal Investigators: 
Institution: 
Award Amount: 
£28,600

This proposal aims to develop new bioactive materials to improve clinical outcomes for patients suffering from bone sarcoma. The developed materials will provide a control release of key metal ions to induce tumour cell death and simultaneously stimulate grow new bone. In addition the material will contain natural antibacterial agents to reduce the probability of surgical site infections. Furthermore we envisage that the material will enhance blood flow therefore significantly reducing patient healing times.

A pilot study investigating health related quality of life, symptom burden and prognostic markers in advanced soft tissue sarcoma

Principal Investigators: 

Dr Julia Riley, Dr Claire Smith, and Professor Ian Judson

Institution: 
Award Amount: 
£126,409
Duration: 
2 years

This study looks at the quality of life of patients being treated for advanced sarcoma. Prospective means it looks at patients as they go along, which gives stronger data. This is better than retrospective data which looks at events in the past where memory or uncertainty often makes the information unreliable.

People with locally advanced or sarcoma that has spread or whose sarcoma has have had recurred after surgery may only be eligible for palliative treatment so quality of life becomes the primary concern rather than defeating the sarcoma.

Unpicking the genetics of rhabdomyosarcoma’s aggression

Principal Investigators: 

ProfessorJanet Shipley, Dr Zoe Walters, and Dr Edoardo Missiaglia

Award Amount: 
£23,266
Duration: 
1 year

This project is using DNA sequencing technology to identify the genes which make rhabdomyosarcoma a particularly aggressive cancer. Alongside this, the project will look for genes which could be potential drug targets in the treatment of rhabdomyosarcoma.

24. Evaluation of loco-regional delivery of oncolytic virotherapy in a rat model of isolated limb perfusion

Principal Investigators: 

Professor Kevin Harrington and Dr Tim Pencavel

Award Amount: 
£30,014
Duration: 
2 years

This is an example of a translational research project, looking at ways to transfer results from the laboratory into a clinical trial in patients in a Phase 1 Trial. They are developing a system for treating limb sarcomas using Isolated Limb Perfusion (ILP) as well as oncolyic virotherapy (anti-cancer viruses)

Defects of DNA repair genes and cell cycle regulators as a predisposing cause of Sarcomas

Principal Investigators: 

Dr Karen Sisley, Dr Abdulazeez Salawu, and Dr Martin Robinson

Award Amount: 
£75,790
Duration: 
3 years

This is a basic science project, finding out more about how chromosome abnormalities in the nuclei of sarcoma cells might upset the regulation of cell turnover. If they can understand more about this it might be an opening to developing new approaches to treatment. 

Understanding how bone is destroyed in Ewing’s sarcoma

Principal Investigators: 
Institution: 
Award Amount: 
£17,500
Duration: 
2 years

Ewing’s sarcoma is a highly aggressive bone cancer that causes the bone to be destroyed. This study is looking at the processes by which Ewing’s cells disrupt normal bone biology and cause the destruction of the bone. By understanding the process by which bone is destroyed, treatments can be developed which prevent it from happening.

Studies in angiosarcoma using canine tumours

Principal Investigators: 
Award Amount: 
£17,500
Duration: 
2 years

In humans angiosarcomas are rare, aggressive tumours of blood vessels.  Angiogenesis is the process of new blood vessel formation and is controlled by a number of different growth factors. The researchers think it is likely that these growth factors are important in the development of angiosarcoma, and that treatments targeting these factors will be useful for patients with angiosarcoma.  Whilst human angiosarcoma is rare the tumour is much more common in dogs and it will be seen by vets in their surgeries when your GP will never see a case.

Genomic and expression profiling of recurrent well differentiated and dedifferentiated liposarcomas

Principal Investigators: 

Professor Janet Shipley, Dr Anastasia Constantinidou

Award Amount: 
£25,000
Duration: 
2 years

Liposarcomas are a type of soft tissue sarcoma that arises in fat cells. Well-differentiated (WD) liposarcomas have clear cell walls and a regular appearence under the microscope. De-differentiated (DD) liposarcomas are much messier and irregular. Both are the most frequent subtype of liposarcomas in adults. Well-differentiated liposarcomas can recur looking more like the de-differentiated type. This is associated with increased aggressiveness. In contrast, completely well-differentiated liposarcomas are usually readily curable.

Pages